Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma

  • Michael J. Murphy

Part of the Current Clinical Pathology book series (CCPATH)

Table of contents

  1. Front Matter
    Pages i-xiv
  2. Jochen Utikal, Jürgen C. Becker, Selma Ugurel
    Pages 9-18
  3. Paolo Antonio Ascierto, Maria Libera Ascierto, Mariaelena Capone, Zendee Elaba, Michael J. Murphy, Giuseppe Palmieri
    Pages 19-37
  4. Zendee Elaba, Michael J. Murphy, Philip Kerr, Jane M. Grant-Kels
    Pages 39-48
  5. Cheryl Bilinski, Avery LaChance, Michael J. Murphy
    Pages 49-67
  6. Giovanna Chiorino, Maria Scatolini
    Pages 79-88
  7. Suhu Liu, Suping Ren, Paul M. Howell Jr., Adam I. Riker
    Pages 89-112
  8. Jim Kozubek, Faseeha Altaf, Soheil Sam Dadras
    Pages 113-126
  9. Daniel W. Mueller, Anja K. Bosserhoff
    Pages 127-144
  10. Mark L. Steinberg
    Pages 145-157
  11. Steven J. Ohsie, Basil A. Horst, Alistair Cochran, Scott W. Binder
    Pages 159-176
  12. Basil A. Horst, Steven J. Ohsie, Alistair Cochran, Scott W. Binder
    Pages 177-188
  13. Michael J. Murphy, Karim Rezaul, David K. Han
    Pages 189-194
  14. Mel Ziman, Michael Millward, Robert Pearce, Mark Lee
    Pages 195-208
  15. Sandro Pasquali, Augustinus P. T. van der Ploeg, Simone Mocellin
    Pages 209-226
  16. Qiuzhen Liu, Marianna Sabatino, David F. Stroncek, Ping Jin, Francesco M. Marincola, Ena Wang
    Pages 227-241
  17. Hedwig Stanisz, Thomas Vogt, Knuth Rass
    Pages 247-263
  18. Alessia E. Russo, Ylenia Bevelacqua, Andrea Marconi, Andrea Veronesi, Massimo Libra
    Pages 265-279
  19. Roberta Ferraldeschi, Paul Lorigan
    Pages 281-294
  20. Back Matter
    Pages 319-322

About this book


This book describes both the technologies used in the discovery of melanoma biomarkers and the clinical application of these biomarkers for diagnosis and staging of disease, determination of prognosis, treatment planning, monitoring of response to therapy, identification of novel therapeutic targets and drug development. A broad range of biomarkers (DNA/chromosomal, mRNA, microRNA, mitochondrial DNA, epigenetic and protein) is outlined. As therapies for melanoma become increasingly more target specific, the identification, validation and use of biomarkers will invariably play a greater role in the management of patients with this disease. Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma is an essential resource for oncologists, dermatologists, dermatopathologists, general pathologists with an interest in melanoma, and melanoma researchers.


Epigenetic Biomarkers Lymph Node Disease Serological Disease microRNA Biomarkers

Editors and affiliations

  • Michael J. Murphy
    • 1
  1. 1.Health Center, Department of DermatologyUniversity of ConnecticutFarmingtonUSA

Bibliographic information

  • DOI
  • Copyright Information Springer Science+Business Media, LLC 2012
  • Publisher Name Springer, New York, NY
  • eBook Packages Medicine Medicine (R0)
  • Print ISBN 978-1-60761-432-6
  • Online ISBN 978-1-60761-433-3
  • Buy this book on publisher's site